Tirzepatide GLP-2 TZ Dosage Protocols: All Vial Sizes
Tirzepatide is a dual GLP-1/GIP receptor agonist studied for type-2 diabetes and chronic weight management. SURMOUNT-1 reported up to 22.5% body-weight reduction at the 15 mg weekly dose. Choose your vial size below; each size has its own exact dosing table.
Choose Your Vial Size
| Vial | Final volume | Concentration | One U-100 unit | |
|---|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 25 mcg in 0.01 mL | Open protocol → |
| 10 mg | 2 mL | 5 mg/mL | 50 mcg in 0.01 mL | Open protocol → |
| 15 mg | 2 mL | 7.5 mg/mL | 75 mcg in 0.01 mL | Open protocol → |
| 20 mg | 2 mL | 10 mg/mL | 100 mcg in 0.01 mL | Open protocol → |
| 30 mg | 3 mL | 10 mg/mL | 100 mcg in 0.01 mL | Open protocol → |
| 40 mg | 2 mL | 20 mg/mL | 200 mcg in 0.01 mL | Open protocol → |
| 50 mg | 2.5 mL | 20 mg/mL | 200 mcg in 0.01 mL | Open protocol → |
| 60 mg | 3 mL | 20 mg/mL | 200 mcg in 0.01 mL | Open protocol → |
Doses are the same research amounts across sizes; the vial size changes the concentration, so syringe units differ. Always use the table for your exact vial.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
Tirzepatide is a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors with a single molecule. GLP-1 activation slows gastric emptying, increases satiety, and stimulates glucose-dependent insulin secretion. GIP activation augments insulin secretion further and modulates fat-cell metabolism.
The molecule is fatty-acid acylated to bind albumin and persist in circulation for once-weekly dosing.
Potential Benefits & Side Effects
Potential Benefits
- SURMOUNT-1: 20.9% weight reduction at 15 mg weekly over 72 weeks vs 3.1% placebo.
- SURPASS-2 (T2DM): HbA1c reduction up to 2.46% at 15 mg.
- Greater outcomes than single-agonist comparators in head-to-head trials.
- Improvement in lipid profile and waist circumference reported alongside weight loss.
Side Effect Profile
- Nausea (most common, dose-dependent).
- Diarrhea and vomiting (more common at higher doses).
- Decreased appetite (intended effect).
- Constipation in some users.
- Rare: pancreatitis, gallbladder events.
Lifestyle Factors
- Aggressive hydration — incretin agonists blunt thirst sensation.
- Protein 1.0–1.6 g/kg/day preserves lean mass during weight loss.
- Resistance training 2–3×/week mitigates muscle loss in caloric deficit.
- Avoid high-fat or large-volume meals around dosing.
- Pace meals slowly; eat to 80% fullness rather than past it.
Injection Technique
- Inject subcutaneously into abdomen (away from navel), outer thigh, or upper arm.
- Rotate sites with each weekly dose.
- 90° angle with short insulin needles (4–8 mm).
- Bring vial to room temperature 15 min before injecting.
- Hold 5 seconds after full plunger depression before withdrawing.